HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norov... HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. 더 보기
$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in...
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus...
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a...
The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.08 | -4.12371134021 | 1.94 | 1.94 | 1.78 | 130171 | 1.82048545 | CS |
4 | 0.03 | 1.6393442623 | 1.83 | 2.015 | 1.78 | 134690 | 1.88779594 | CS |
12 | -0.03 | -1.5873015873 | 1.89 | 2.015 | 1.68 | 184178 | 1.82275354 | CS |
26 | -12.58 | -87.1191135734 | 14.44 | 15.6 | 1.55 | 641178 | 2.54386912 | CS |
52 | -12.08 | -86.6571018651 | 13.94 | 20.22 | 1.55 | 401784 | 4.92298843 | CS |
156 | -16.9 | -90.0852878465 | 18.76 | 24.42 | 1.55 | 211831 | 7.56908837 | CS |
260 | -16.9 | -90.0852878465 | 18.76 | 24.42 | 1.55 | 211831 | 7.56908837 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관